WO2020032261A1 - エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法 - Google Patents
エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法 Download PDFInfo
- Publication number
- WO2020032261A1 WO2020032261A1 PCT/JP2019/031652 JP2019031652W WO2020032261A1 WO 2020032261 A1 WO2020032261 A1 WO 2020032261A1 JP 2019031652 W JP2019031652 W JP 2019031652W WO 2020032261 A1 WO2020032261 A1 WO 2020032261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- microorganism
- orfb
- epa
- genus
- Prior art date
Links
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 115
- 244000005700 microbiome Species 0.000 title claims abstract description 108
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 102
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 102
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 97
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 103
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 94
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 28
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 12
- 150000001413 amino acids Chemical group 0.000 claims description 93
- 239000000203 mixture Substances 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 17
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 13
- 241001306132 Aurantiochytrium Species 0.000 claims description 11
- 108700016155 Acyl transferases Proteins 0.000 claims description 6
- 102000057234 Acyl transferases Human genes 0.000 claims description 6
- 241000588722 Escherichia Species 0.000 claims description 5
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 241000233675 Thraustochytrium Species 0.000 claims description 5
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 claims description 5
- 230000037353 metabolic pathway Effects 0.000 claims description 5
- 241001306135 Oblongichytrium Species 0.000 claims description 4
- 241001138695 Parietichytrium Species 0.000 claims description 4
- 241000233671 Schizochytrium Species 0.000 claims description 4
- 241001491678 Ulkenia Species 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000186216 Corynebacterium Species 0.000 claims description 3
- 241000235648 Pichia Species 0.000 claims description 3
- 108010030975 Polyketide Synthases Proteins 0.000 claims description 3
- 101710142619 3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ Proteins 0.000 claims description 2
- 102000004867 Hydro-Lyases Human genes 0.000 claims description 2
- 108090001042 Hydro-Lyases Proteins 0.000 claims description 2
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 claims description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 claims description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 241000235013 Yarrowia Species 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 108010019608 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase Proteins 0.000 claims 1
- 102100037149 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial Human genes 0.000 claims 1
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 55
- 235000018102 proteins Nutrition 0.000 description 47
- 241000588724 Escherichia coli Species 0.000 description 45
- 238000000034 method Methods 0.000 description 42
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 33
- 229960003136 leucine Drugs 0.000 description 32
- 239000004395 L-leucine Substances 0.000 description 28
- 235000019454 L-leucine Nutrition 0.000 description 28
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 25
- 239000012634 fragment Substances 0.000 description 25
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 16
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 15
- 108091008146 restriction endonucleases Proteins 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 229960005190 phenylalanine Drugs 0.000 description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 13
- 239000013613 expression plasmid Substances 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 12
- 238000010276 construction Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 229960001153 serine Drugs 0.000 description 9
- 229960001230 asparagine Drugs 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229930027917 kanamycin Natural products 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 239000002773 nucleotide Chemical group 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 229960005322 streptomycin Drugs 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 229960005261 aspartic acid Drugs 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229960002449 glycine Drugs 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 229960003767 alanine Drugs 0.000 description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 5
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229960002898 threonine Drugs 0.000 description 5
- 241001130339 Aurantiochytrium sp. Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical group [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- WIIZWVCIJKGZOK-IUCAKERBSA-N 2,2-dichloro-n-[(1s,2s)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@@H](CO)[C@@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-IUCAKERBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229910015900 BF3 Inorganic materials 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000144181 Thraustochytrium aureum Species 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000003570 biosynthesizing effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- -1 -Methionine Chemical compound 0.000 description 2
- XQFCCTPWINMCQJ-UHFFFAOYSA-N 1-(1H-indol-3-yl)-N,N-dimethylpropan-2-amine Chemical compound CC(N(C)C)CC1=CNC2=CC=CC=C12 XQFCCTPWINMCQJ-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000003610 Aplanochytrium Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000003595 Aurantiochytrium limacinum Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 241000199913 Crypthecodinium Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001467578 Microbacterium Species 0.000 description 2
- 101710160066 Mitochondrial holo-[acyl-carrier-protein] synthase Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000863430 Shewanella Species 0.000 description 2
- 241000546140 Stigeoclonium Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 241000186254 coryneform bacterium Species 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000004808 supercritical fluid chromatography Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- YOFPFYYTUIARDI-ZCFIWIBFSA-N (2r)-2-aminooctanedioic acid Chemical group OC(=O)[C@H](N)CCCCCC(O)=O YOFPFYYTUIARDI-ZCFIWIBFSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical group [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101710146995 Acyl carrier protein Proteins 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241001491231 Aphanochaete Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 description 1
- 241000162592 Aurantiochytrium limacinum ATCC MYA-1381 Species 0.000 description 1
- 241001460991 Aureispira Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 239000005746 Carboxin Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000200138 Ceratium Species 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241001491656 Chrysochromulina Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241000807905 Corynebacterium glutamicum ATCC 14067 Species 0.000 description 1
- 241000195618 Cryptomonas Species 0.000 description 1
- 102100023578 Cyclic AMP-dependent transcription factor ATF-7 Human genes 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241001221643 Diacronema Species 0.000 description 1
- 241000391095 Dinobryon Species 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 241000196133 Dryopteris Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- 241000195623 Euglenida Species 0.000 description 1
- 241000224472 Eustigmatophyceae Species 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710150242 Glutamate decarboxylase A Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000866505 Gyrodinium Species 0.000 description 1
- 101000905723 Homo sapiens Cyclic AMP-dependent transcription factor ATF-7 Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001491670 Labyrinthula Species 0.000 description 1
- 101710098556 Lipase A Proteins 0.000 description 1
- 101710099648 Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- 101001014220 Monascus pilosus Dehydrogenase mokE Proteins 0.000 description 1
- 241000294598 Moritella marina Species 0.000 description 1
- 241000159660 Nannochloropsis oculata Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000192673 Nostoc sp. Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 1
- 241000199478 Ochromonas Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 241000200172 Oxyrrhis Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 101000573542 Penicillium citrinum Compactin nonaketide synthase, enoyl reductase component Proteins 0.000 description 1
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 241000199911 Peridinium Species 0.000 description 1
- 241000593473 Platychrysis Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241001491792 Prymnesium Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101150114644 Rapgef3 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001501882 Rhodomonas Species 0.000 description 1
- 241000598397 Schizochytrium sp. Species 0.000 description 1
- 102000019394 Serine hydroxymethyltransferases Human genes 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001466451 Stramenopiles Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- QWDCYFDDFPWISL-UHFFFAOYSA-N UNPD207407 Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OC QWDCYFDDFPWISL-UHFFFAOYSA-N 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 101150044776 URA5 gene Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000206764 Xanthophyceae Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- GYSSRZJIHXQEHQ-UHFFFAOYSA-N carboxin Chemical compound S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 GYSSRZJIHXQEHQ-UHFFFAOYSA-N 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- VCDLWFYODNTQOT-UHFFFAOYSA-N docosahexaenoic acid methyl ester Natural products CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OC VCDLWFYODNTQOT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- KYOBSHFOBAOFBF-XVFCMESISA-N orotidine 5'-phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-XVFCMESISA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/10—Protozoa; Culture media therefor
- C12N1/105—Protozoal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/90—Protozoa ; Processes using protozoa
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Definitions
- the present invention relates to a microorganism that produces eicosapentaenoic acid and a method for producing eicosapentaenoic acid using the microorganism.
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- ARA arachidonic acid
- DPA docosapentaenoic acid
- PUFAs polyunsaturated fatty acids
- PUFA is known to have various physiological functions such as prevention of arteriosclerosis and hyperlipidemia (Non-Patent Documents 1 and 2).
- PUFA-PKS polyunsaturated fatty acid polyketide synthase
- the anaerobic pathway by PUFA-PKS is a pathway for synthesizing PUFA from acetyl-CoA or malonyl-CoA, and is known to have some marine bacteria and eukaryotes of Labyrinthura (Non-Patent Document) 4 and Non-Patent Document 5).
- PUFA-PKS is a complex enzyme composed of a plurality of proteins (hereinafter, also referred to as a protein complex), and each protein has a plurality of functional domains related to the synthesis of PUFA.
- Functional domains present in PUFA-PKS include ⁇ -ketoacyl-acyl carrier protein synthase domain (hereinafter referred to as KS domain) and phosphopantetheinyl group, which are considered to be involved in the condensation of malonyl-ACP and acyl-ACP.
- KS domain ⁇ -ketoacyl-acyl carrier protein synthase domain
- phosphopantetheinyl group which are considered to be involved in the condensation of malonyl-ACP and acyl-ACP.
- An acyl carrier protein domain (hereinafter, referred to as an ACP domain) which is supposed to function as a site for fatty acid synthesis by bonding to an acyl group via a thioester bond, and a ketoreductase domain which is supposed to reduce a carbonyl group generated by condensation (
- a KR domain a DH domain that is supposed to form a double bond by dehydrating a hydroxyl group generated by the KR domain, and a chain elongation factor domain that is involved in carbon chain elongation
- ER domain Enoyl reductase domain
- AT domain an acyltransferase domain
- AT domain malonyl-CoA: acyltransferase domain (hereinafter, referred to as AT domain).
- MAT domain MAT domain
- PPT domain phosphopantethein transferase domain
- PUFA-PKS produces different types of PUFA depending on the type. For example, Schizochyrium @ sp. Aurantiochytrium @ sp. And PUFA-PKS derived from Moritela @ marina, DHA, PUFA-PKS derived from Shewanella @ oneidensis and Photobacterium @ profundum, EPA, and Aureispira @ marina produced mostly as PU, and almost no ARA was produced as PU. Or, even if it is produced, it is small compared to the main product.
- Non-patent Documents 4 and 6 discuss the production of PUFA by cloning the PUFA-PKS gene from bacteria of the genus Shewanella or eukaryotes of stramenopiles and expressing the gene in a heterologous organism.
- Non Patent Literature 7 discloses that ATFA is a study using the pfaB gene, which is a constituent gene of PUFA-PKS derived from Moritella marina that produces DHA, and the pfaB gene that constitutes PUFA-PKS, which is derived from Shewanella um pneumatophori that produces EPA. It is disclosed that the pfaB gene encoding the domain is involved in the type of PUFA produced.
- Non-Patent Document 8 discloses that introduction of the DH domain of PUFA-PKS derived from the genus Thraustochytrium into Escherichia coli increases the production of fatty acids and the proportion of unsaturated fatty acids.
- Patent Document 2 As an industrial production method of EPA, a method such as purification from fish oil is known, but there is a problem that there are many by-products (Patent Document 2).
- an object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism.
- PUFA containing EPA at a high concentration can be produced by expressing OrfB in which a mutation has been introduced into a specific amino acid residue in a microorganism having the ability to produce DHA. Completed.
- the present invention relates to the following.
- a microorganism capable of producing DHA wherein at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 is another amino acid residue.
- a microorganism comprising a protein consisting of an amino acid sequence substituted with hereinafter, referred to as mutant OrfB
- mutant OrfB mutant OrfB
- EPA eicosapentaenoic acid
- a microorganism comprising a protein comprising a substituted amino acid sequence (hereinafter referred to as a mutant OrfB homolog) and capable of producing EPA. 3.
- Labyrinthura microorganisms are of the genus Aurantiochytrium, the genus Thraustochytrium, the genus Ulkenia, the genus Parietichytrium, the genus Labyrinthuraium, Labyrinthuraium, Labyrinthuraium and Labyrinthuraium. 4.
- the microorganism having the ability to produce DHA is a microorganism into which a gene encoding each of the following domains (a) to (j) having an activity of synthesizing DHA is introduced into a microorganism having no DHA metabolic pathway. Or the microorganism according to 2.
- KS domain (b) MAT domain (c) ACP domain (d) KR domain (e) polyketide synthase dehydratase (hereinafter referred to as PS-DH) domain (f) CLF domain (g) AT domain (h) FabA -Like ⁇ -hydroxyacyl-ACP dehydratase (hereinafter referred to as FabA-DH) domain (i) ER domain (j) PPT domain
- DHA metabolic pathway include the genus Escherichia, the genus Bacillus, the genus Corynebacterium, the genus Yarrowia, the genus Saccharomyces, or the genus Saccharidica, Candidapid.
- An EPA comprising culturing the microorganism according to any one of 1 to 6 above in a medium, producing and accumulating EPA or an EPA-containing composition in the culture, and collecting EPA or the EPA-containing composition from the culture. Or a method for producing an EPA-containing composition.
- the amino acid sequence represented by SEQ ID NO: 2 at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 of SEQ ID NO: 2 was replaced with another amino acid residue
- a microorganism comprising a mutant OrfB homolog consisting of a modified amino acid sequence and capable of producing EPA
- the microorganism of the present invention efficiently produces EPA by introducing a mutation into a specific amino acid residue and expressing a mutant OrfB having a changed specificity for a substrate in a microorganism having the ability to produce DHA. it can.
- the method for producing EPA of the present invention can produce EPA at low cost and with high efficiency by expressing mutant OrfB in a microorganism capable of producing DHA at an industrial level. Applicable to production.
- FIG. 1 shows a schematic diagram of the structure of PUFA-PKS belonging to the genus Aurantiochytrium (sp.).
- FIG. 2 shows an example of the result of alignment of the amino acid sequences of OrfB and OrfB homologs.
- polyunsaturated fatty acid refers to a long-chain fatty acid having a carbon chain length of 18 or more and an unsaturated bond number of 2 or more.
- domain refers to a part consisting of a continuous amino acid sequence in a protein, and is a region having a specific biological activity or function in the protein.
- PUFA-PKS has the same meaning as PUFA @ synthase.
- PUFA @ synthase is a group of enzymes that synthesize specific long-chain unsaturated fatty acids using malonyl-CoA or the like as a carbon source, and includes KS, MAT, ACP, KR, PS-DH, CLF, AT, FabA-DH. , ER, and PPTase domains (ACOS Lipid Library: PUFA synthase; Science, 2001, 293, 290-293; PLoS One, 2011, 6, e20146, etc.).
- KS domain is a domain of a protein constituting a protein complex having PUFA-PKS activity, and refers to a domain involved in the condensation of malonyl ACP and acyl ACP.
- the MAT domain and AT domain are domains of a protein constituting a protein complex having PUFA-PKS activity, and refer to domains involved in acyl group transfer.
- the ACP domain is a domain of a protein constituting a protein complex having PUFA-PKS activity.
- the ACP domain binds to an acyl group via a phosphopantetheinyl group via a thioester bond, and functions as a place of fatty acid synthesis. -Refers to domains essential for PKS activity.
- KR domain is a domain of a protein constituting a protein complex having PUFA-PKS activity, and refers to a domain involved in reduction of a ketone group generated by condensation.
- PS-DH domain and FabA-DH domain which are DH domains, are domains of a protein constituting a protein complex having PUFA-PKS activity, and are domains involved in dehydration of a hydroxyl group generated by reducing a ketone group.
- the CLF domain is a domain of a protein constituting a protein complex having PUFA-PKS activity, and refers to a domain involved in carbon chain elongation.
- the ER domain is an acyltransferase domain
- the malonyl-CoA: ACP acyltransferase domain is a domain of a protein constituting a protein complex having PUFA-PKS activity and is a domain involved in acyl group transfer.
- PPTase is an enzyme that constitutes a protein complex having PUFA-PKS activity, and refers to an enzyme involved in activation of the ACP domain.
- the term “foreign” refers to a substance that is not endogenous but derived from a heterologous organism. If the host organism before transformation does not have a gene to be introduced according to the present invention, it is encoded by the gene. When the protein according to the present invention is substantially not expressed, or when the amino acid sequence of the protein is encoded by a different gene but the activity of the endogenous protein is not expressed after the transformation, the gene according to the present invention is introduced into the host organism. Used to mean to do.
- the microorganism of the present invention is a microorganism having the ability to produce docosahexaneenoic acid (DHA), and has the sixth, 65th, 230th, 231st and 275th amino acids in the amino acid sequence represented by SEQ ID NO: 2. It contains a protein consisting of an amino acid sequence in which at least one of the amino acid residues is substituted by another amino acid residue (mutant OrfB), and is capable of producing eicosapentaenoic acid (EPA).
- DHA docosahexaneenoic acid
- Microorganisms capable of producing DHA include the following (1) and (2).
- a microorganism having a DHA-producing ability by introducing genes encoding PS-DH domain, CLF domain, AT domain, FabA-DH domain, ER domain and PPT domain.
- the term “host organism” refers to an original organism to be subjected to genetic modification, transformation, and the like.
- the original organism to be transformed by gene transfer is a microorganism, it is also referred to as a parent strain or a host strain.
- microorganisms having DHA metabolizing ability include microorganisms belonging to Labyrinthuras.
- microorganisms belonging to Labyrinthuras include, for example, genus Aurantiochytrium, genus Thraustochytrium, genus Ulkenia, genus Parietichytrium (Pariethychytrium), genus Labyrinthura (Prabythura) and Labyrinthura Microorganisms of the genus Chanitorium (Aplanochytrium), the genus Oblongichytrium, or the genus Schizochytrium can be mentioned.
- Aurantiochytrium limacinum (Aurantiochytrium limacinum), Thraustochytrium aureum (Thraustochytrium aureum) and the like are included, but are not limited to these as long as they naturally have a DHA metabolic pathway.
- microorganism having DHA metabolism ability specifically, for example, a microorganism belonging to the genus Aurantiochytrium is preferable, and for example, Aurantiochytrium SP sp. OH4 strain (Accession number FERM BP-11524) and the like can be mentioned. Further, a microorganism having a DHA-producing ability, which is a mutant thereof, may be used.
- the Aurantiochytrium sp. OH4 strain was deposited under the Patent Microorganisms Depositary of the National Institute of Technology and Evaluation (NITE), located at 1-1, Higashi 1-1, Tsukuba, Ibaraki, Japan, postcode 305-8566. Deposited at the center.
- the date of receipt (deposit date) is January 11, 2013 (AD 2013), and the deposit number is FERM @ BP-11524.
- the microorganism having no DHA metabolizing ability is a microorganism having no DHA producing ability by nature.
- examples of the microorganisms having no DHA metabolism ability include bacteria, microalgae, fungi, protists, and protozoa.
- bacteria examples include, for example, genus Escherichia, genus Serratia, genus Bacillus, genus Brevibacterium, genus Corynebacterium, genus Microbacterium, and genus Microbacterium. Pseudomonas) and microorganisms belonging to one genus selected from the group consisting of Aureispira.
- Escherichia coli XL1-Blue Escherichia coli XL2-Blue
- Escherichia coli DH1 Escherichia coli MC1000
- Escherichia coli KY3276 Escherichia coli W1485, Escherichia coli JM109, Escherichia coli HB101
- microalgae examples include, for example, Euglenophyceae (eg, Euglena genus and Peranema genus), green algae (Chrysophyceae) [eg, genus Ochromonas], Dayacenayg.
- Euglenophyceae eg, Euglena genus and Peranema genus
- Chrysophyceae green algae [eg, genus Ochromonas]
- Dayacenayg By way of example, the genus Dinobryon, the genus Platychrysis and the genus Chrysochromulina]
- Dinophyceae eg the genus Crypthecodinium, G.
- Peridinium Peridinium genus, Seratium (Ceratium) genus, Giroji Genus Gyrodinium and Oxyrrhis], Cryptophyceae (for example, Cryptomonas and Rhodomonas), Xanthophyceae (x) s.
- the genus [and the flagellate lysochlorides (Rhizochloridaceae) and Afanocaete pascheri (Aphanochaete pascheri), Bumileria stigeoclonium (Bumilliaria stigeoclonium) and the spores of Baukeria Geminata (Ag.
- Algae that produce such an amoebic phase The containing, authentic methene Motsuna (Eustigmatophyceae) and Purimuneshiumu Motsuna (Prymnesiopyceae) [for example, Purimuneshiumu (Prymnesium) genus and Diakuronema (Diacronema) including genus.
- ⁇ ⁇ ⁇ ⁇ Preferred species within these genera are not particularly limited, but include Nannochloropsis oculata, Crypthecodinium cohniii, and Euglena gracilis.
- Fungi include, for example, the genus Saccharomyces (for example, Saccharomyces cerevisiae), yeasts containing the genus Saccharomyces carsbergensis, Saccharomyces carsbergensis, and yeasts of the genus Kia dia ard ai and the genus Kia dia (Yaida) and the genus Kia ai ai darica (Yaida).
- Other yeasts such as the genus (Pichia), the genus Kluyveromyces, or other fungi, for example, filamentous fungi such as the genus Aspergillus, the genus Neurospora, the genus Penicillium. And the like.
- Cell lines that can be used as host cells may be wild-type in the usual sense, or may be auxotrophic mutants, antibiotic-resistant mutants, and are transformed to have various marker genes. It may be. For example, strains showing resistance to antibiotics such as chloramphenicol, ampicillin, kanamycin, tetracycline and the like can be mentioned.
- each domain constituting PUFA-PKS having an activity of biosynthesizing DHA in order to allow a microorganism having no DHA metabolizing ability to acquire DHA producing ability includes the above-mentioned (1) DHA
- Each domain constituting PUFA-PKS is not limited, as long as the domain cooperates to produce DHA.
- each domain of known PUFA-PKS can be mentioned.
- cognate means that when a certain protein is allowed to coexist with another protein, a specific reaction is integrally performed.
- the term “cooperate” is necessary for PUFA-PKS activity. This means that when a plurality of domains coexist, they exhibit PUFA-PKS activity together with other domains.
- the “known PUFA-PKS” is preferably a genus of Aurantiochytrium, a genus of Thraustochytrium, a genus of Ulkenia, a genus of Parietichytrium, or Labyrinthura.
- PUFA-PKS originally possessed by a microorganism belonging to a genus selected from the group consisting of the genus (Labyrinthula), the genus Aplanochytrium, the genus Oblongichytrium, or the genus Schizochytrium, More preferably, Aurantiochytrium limacinum ATCC MYA-1381, Schizo hytrium sp.
- the microorganisms selected from the group consisting of ATCC # 20888 and Thraustochytrium Aureum ATCC # 34304 include PUFA-PKS which is originally possessed by microorganisms.
- PUFA-PKS is a protein complex (complex enzyme) composed of a plurality of proteins having the above domains
- OrfB is a protein constituting PUFA-PKS.
- FIG. 1 shows a schematic diagram of a domain structure constituting a protein complex of PUFA-PKS in a microorganism belonging to the genus Aurantiochytrium (Sp.).
- OrfB there is one KS domain, CLF domain, AT domain, and ER domain.
- mutant OrfB examples include proteins described in the following (a) or (b).
- A a protein comprising an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue;
- B In the amino acid sequence of the OrfB homolog, when this amino acid sequence is aligned with the amino acid sequence represented by SEQ ID NO: 2, the sixth, 65th, 230th, and 231rd amino acids of the amino acid sequence represented by SEQ ID NO: 2
- a protein comprising an amino acid sequence in which at least one of the amino acid residues corresponding to the amino acid residues 275 and 275 is substituted with another amino acid residue.
- At least the amino acid residue at position 230 in the amino acid sequence represented by SEQ ID NO: 2 is preferably replaced with another amino acid residue. It is more preferable that at least one selected from the amino acid residues at positions 6, 65, 231, and 275 is substituted with another amino acid residue. And 230th amino acid residue, 6th, 65th and 230th amino acid residues or 65th, 230th, 231st and 275th amino acid residues are particularly substituted with other amino acid residues. preferable.
- the amino acid sequence of the OrfB homolog when the amino acid sequence of the OrfB homolog is aligned with the amino acid sequence represented by SEQ ID NO: 2 in the amino acid sequence of the OrfB homolog, at least the amino acid sequence represented by SEQ ID NO: 2 It is preferable that the amino acid residue corresponding to the 230th amino acid residue is substituted with another amino acid residue.
- the 6th, 65th and 230th amino acid residues or the 65th and 230th amino acid residues are substituted with another amino acid residue.
- the OrfB homologue is composed of an amino acid sequence having high homology to the amino acid sequence represented by SEQ ID NO: 2, and is similar in structure and function to OrfB having the amino acid sequence represented by SEQ ID NO: 2, whereby the protein is identified. Is a protein possessed by a naturally occurring organism, which is considered to have the same evolutionary origin as the gene encoding the original protein.
- OrfB homologues include PhoC derived from Photobacterium @ profundum represented by SEQ ID NO: 27, EpaC derived from Shewanella @ oneidensis represented by SEQ ID NO: 28, DhaC derived from Moritella @ marina represented by SEQ ID NO: 29, and SEQ ID NO: 30.
- AraC derived from Aureispira @ marina represented by Schizochytrium @ sp. (ATCC20888) -derived OrfB and the like.
- FIG. 2 shows an example of the result of the alignment of the amino acid sequence between OrfB and the OrfB homolog.
- the alignment of the amino acid sequence can be prepared using a known alignment program ClustalW [Nucelic Acids Research 22, 2273, (1994)].
- ClustalW is available at http: // www. ebi. ac. Available from uk / clustalw / (European Bioinformatics @ Institute). For example, a default value is used as a parameter when creating an alignment using ClustalW.
- the mutant OrfB is a protein in which at least one of the following amino acid residues has been substituted in the amino acid sequence of the protein described in (a) or (b) above.
- the sixth amino acid residue of the amino acid sequence of SEQ ID NO: 2 or the amino acid residue corresponding to the amino acid residue of the amino acid sequence of the OrfB homolog is substituted with serine;
- the 65th amino acid residue of the amino acid sequence of SEQ ID NO: 2 An amino acid residue or an amino acid residue corresponding to the amino acid residue of the amino acid sequence of the OrfB homolog is substituted with leucine
- leucine iii) the amino acid residue at position 230 in the amino acid sequence of SEQ ID NO: 2 or the amino acid residue of the amino acid sequence of the OrfB homolog;
- the amino acid residue corresponding to the group is replaced with leucine, L-tryptophan, L-asparagine, glycine, L-aspartic acid or L-alanine (iv) the amino
- the amino acid residue after the above substitution may be an amino acid that can be mutually substituted.
- the following shows examples of amino acids that can be substituted for each other.
- Amino acids included in the same group can be substituted for each other.
- Group A leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, O-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine
- B group aspartic acid, glutamic acid, isoaspartic acid, Isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid group
- C asparagine, glutamine group
- D lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid group
- E proline, 3 -Hyd
- the amino acids to be substituted may be natural or non-natural.
- natural amino acids include L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-arginine, L-arginine, -Methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine and the like.
- Methods for expressing a mutant OrfB or a mutant OrfB homolog in a microorganism having the ability to produce DHA include, for example, the following (I) and (II).
- (I) A foreign gene encoding a mutant OrfB or a mutant OrfB homolog is introduced into a microorganism having the ability to produce DHA.
- introduction of a foreign gene encoding a mutant OrfB or a mutant OrfB homolog may be performed by introducing the gene to be replaced in the cell of the host organism when the plasmid is present in a cell of the host organism as an autonomously replicable plasmid. Is replaced with a corresponding foreign gene, which includes the case where a foreign gene encoding a mutant OrfB or a mutant OrfB homolog is incorporated into a region of the chromosomal DNA of the cell other than the gene encoding OrfB.
- the term “gene” refers to a DNA that may contain a transcription control region, a promoter region, a terminator region, and the like in addition to a protein coding region.
- the DNA should be a suitable distance (eg, 6 to 18 bases) between the Shine-Dalgarno sequence, which is a ribosome binding region, and the initiation codon. It is preferable to use a plasmid adjusted to the above.
- a transcription termination factor is not always necessary for expression of the DNA, but it is preferable to arrange a transcription termination sequence immediately below the structural gene.
- a recombinant gene inserted downstream of a promoter of an appropriate expression vector can be introduced into a host cell.
- the expression vector includes a promoter, a transcription termination signal, a selection marker gene for selecting a transformant (for example, kanamycin resistance gene, streptomycin resistance gene, carboxin resistance gene, zeocin resistance gene, drug resistance such as hygromycin resistance gene, etc.).
- marker genes include orotidine-5'-phosphate decarboxylase gene (ura3 gene) and orotidylate pyrophosphorylase gene (ura5 gene).
- a promoter is defined as a DNA base sequence that initiates RNA synthesis by binding RNA polymerase to DNA, regardless of whether it is a constitutive promoter or a regulated promoter.
- a strong promoter is a promoter that initiates mRNA synthesis at a high frequency and is preferably used.
- lac system, trp system, TAC or TRC system, major operator and promoter regions of ⁇ phage, control region of fd coat protein, glycolytic enzymes (eg, 3-phosphoglycerate kinase, glyceraldehyde-3-phosphate dehydration) Promoters, glutamate decarboxylase A, and serine hydroxymethyltransferase can be used depending on the properties of the host cell.
- regulatory elements include, for example, selectable markers, amplification signals, origins of replication, and the like.
- Preferred regulatory sequences include, for example, the sequences described in “Gene Expression Technology: Methods in Enzymology 185” and Academic Press (1990).
- the vector there is no particular limitation on the vector as long as the gene of interest can be expressed. No particular limitation is imposed on the type of reagents for constructing the vector, for example, restriction enzymes or ligation enzymes, and commercially available products can be used as appropriate.
- the promoter in the case of using a Labyrinthura microorganism as a host organism is not particularly limited as long as it is a promoter that functions in the cells of the Labyrinthura microorganism, and examples thereof include an actin promoter, a tubulin promoter, an Elongation factor Tu promoter, and a promoter.
- An example is a sugar gene expression promoter.
- pColdI manufactured by Takara Bio Inc.
- pET21a pCOLADuet-1
- pACYCDuet-1 pCDF-1b
- pRSF-1b manufactured by Novagen
- pGEL1 Proc. Natl. Acad. Sci. USA, 82, 4306 (1985)]
- pBluescriptII @ SK (+), pBluescriptII @ KS (-) manufactured by Stratagene
- pTrS30 Escherichia coli JM109 / pTrS30 (adjusted from Ferm @ BP-5407), pTrA32] ⁇ Adjusted from Kori JM109 / pTrS32 (Ferm BP-5408)]
- pTK31 [APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2007, Vol. 73, no.
- pPAC31 (WO 98/12343), pUC19 [Gene, 33, 103 (1985)], pSTV28 (Takara Bio Inc.), pUC118 (Takara Bio Inc.), pPA1 (Japan JP-A-63-233798), pHSG298 (manufactured by Takara Bio Inc.), and pUC18 (manufactured by Takara Bio Inc.).
- the promoter in the case of using the above-mentioned expression vector is not particularly limited as long as it functions in a cell of a microorganism belonging to the genus Escherichia.
- a trp promoter Ptrp
- lac lac promoter
- PL promoter PL promoter
- PR promoter PR promoter
- PSE promoter T7 promoter and the like
- promoters derived from Escherichia coli, phage and the like promoters derived from Escherichia coli, phage and the like.
- a promoter artificially designed and modified such as a promoter in which two Ptrps are connected in series, a tac promoter, a trc promoter, a lacT7 promoter, and a letI promoter are exemplified.
- examples of expression vectors include pCG1 (Japanese Patent Application Laid-Open No. 57-134500), pCG2 (Japanese Patent Application Laid-Open No. 58-35197), and pCG4 (Japanese Patent Application Laid-Open No. 58-35197). JP-A-57-183799), pCG11 (JP-A-57-134500), pCG116, pCE54, and pCB101 (all of which are JP-A-58-105999), pCE51, pCE52, and pCE53 [any of them] Molecular and General ⁇ Genetics, 196, 175 (1984)].
- the promoter is not particularly limited as long as it is a promoter that functions in a coryneform bacterium cell.
- a P54-6 promoter Appl. Microbiol. Biotechnol. , 53, 674-679 (2000).
- examples of expression vectors include YEp13 (ATCC37115), YEp24 (ATCC37051), YCp51 (ATCC37419), pHS19, and pHS15.
- the promoter in the case of using the expression vector is not particularly limited as long as it is a promoter that functions in cells of a yeast strain.
- a PH05 promoter, a PGK promoter, a GAP promoter, an ADH promoter, a gal @ 1 promoter, a gal @ 10 promoter, Promoters such as a heat shock polypeptide promoter, an MF ⁇ 1 promoter, and a CUP1 promoter are exemplified.
- a homologous recombination method As a method of integrating the recombinant gene into the chromosome of the host organism, a homologous recombination method can be used.
- the homologous recombination method include a method of introducing a recombinant gene using a homologous recombination system that can be prepared by ligating a plasmid DNA having a drug resistance gene that cannot be autonomously replicated in a parent strain to be introduced.
- a method using homologous recombination frequently used in Escherichia coli a method of introducing a recombinant gene using a homologous recombination system of lambda phage [Proc. Natl. Acad. Sci. USA, 97, 6641-6645 (2000)].
- a selection method utilizing the fact that Escherichia coli becomes sucrose-sensitive by the Bacillus subtilis levan sucrose integrated on the chromosome together with the recombinant gene A selection method utilizing the fact that E. coli becomes streptomycin sensitive by integration [Mol. Microbiol. , 55, 137 (2005); Biosci. Biotechnol. Biochem. , 71, 905 (2007)] can be used to obtain a microorganism in which the target region on the chromosomal DNA of the parent strain has been replaced with the recombinant DNA.
- the present invention includes, but is not limited to, an improved method of the ATMT method.
- a method for introducing a gene to be introduced as a plasmid autonomously replicable in a host organism for example, a method using calcium ions [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], the protoplast method (Japanese Patent Application Laid-Open No. 63-248394), and the electroporation method [Nucleic Acids Res. , 16, 6127 (1988)].
- microorganism obtained by the above-described method is the target microorganism can be confirmed by culturing the microorganism and detecting EPA accumulated in the culture by gas chromatography.
- the microorganism of the present invention has a EPA / DHA ratio in a final product (PUFA) produced when cultured at 20 ° C. for 48 hours, for example, of 0% as measured by gas chromatography mass spectrometry described later in Examples. It is preferably at least 0.1, more preferably at least 0.2, even more preferably at least 0.5.
- PUFA final product
- the present invention is characterized in that the microorganism thus created is cultured in a medium, EPA or an EPA-containing composition is produced and accumulated in the culture, and the EPA or the EPA-containing composition is collected from the culture.
- a method for producing EPA or an EPA-containing composition hereinafter referred to as the production method of the present invention.
- the EPA-containing composition includes, for example, EPA-containing fats and oils or EPA-containing phospholipids, preferably EPA-containing fats and oils.
- a culture of the microorganism can be obtained by inoculating the microorganism into an appropriate medium and culturing the culture according to a conventional method.
- any known medium containing a carbon source, a nitrogen source, an inorganic salt and the like can be used.
- the carbon source include carbohydrates such as glucose, fructose, and galactose, oils and fats such as oleic acid and soybean oil, glycerol, and sodium acetate. These carbon sources can be used, for example, at a concentration of 20 to 300 g per liter of medium.
- the culture can be continued by feeding the carbon source. By culturing under such conditions, the amount of the carbon source to be consumed can be increased, and the production amount of the EPA-containing composition can be improved.
- the nitrogen source examples include organic nitrogen such as yeast extract, corn steep liquor, polypeptone, sodium glutamate, and urea, and inorganic nitrogen such as ammonium acetate, ammonium sulfate, ammonium chloride, sodium nitrate, ammonium nitrate, and ammonia.
- organic nitrogen such as yeast extract, corn steep liquor, polypeptone, sodium glutamate, and urea
- inorganic nitrogen such as ammonium acetate, ammonium sulfate, ammonium chloride, sodium nitrate, ammonium nitrate, and ammonia.
- potassium phosphate or the like can be appropriately used in combination.
- the medium containing each of the above components is preferably used after adjusting the pH to a range of 4.0 to 9.5 by adding an appropriate acid or base, followed by sterilization by an autoclave.
- the culture temperature is generally from 10 to 45 ° C, preferably from 20 to 37 ° C. It is preferable that the culture temperature is controlled to a culture temperature at which an EPA-containing composition can be produced.
- the pH at the time of culturing is generally 3.5 to 9.5, preferably 4.5 to 9.5.
- the particularly preferred pH varies depending on the purpose, and is from 5.0 to 8.0 in order to produce a large amount of fats and oils.
- the culturing time can be, for example, 2 to 7 days, and the culturing can be performed by aeration and stirring cultivation.
- the method of separating the culture solution and the microorganism from the culture can be performed by a conventional method known to those skilled in the art, for example, by centrifugation or filtration.
- the EPA-containing composition can be obtained by crushing the microorganisms separated from the above-mentioned culture by, for example, ultrasonic waves or dynomill, and then performing solvent extraction with, for example, chloroform, hexane, butanol, or the like.
- the EPA-containing composition produced by the above-mentioned production method can be used, for example, by a low-temperature solvent fractionation method [Shotataro Takahashi, Oil Chemistry, 40: 931-941 (1991)], or a short-chain fatty acid with a hydrolase such as lipase
- a EPA-containing composition having a high EPA content can be obtained by concentrating the EPA-containing composition by a method such as a method of removing acetic acid [Kotaro Takahashi, Oil Chemistry, 40: 931-941 (1991)].
- EP EPA can be manufactured by separating and collecting EPA from the EPA-containing composition. For example, after preparing a mixed fatty acid containing EPA from the EPA-containing composition by a hydrolysis method, EPA is separated by, for example, a urea addition method, a cooling separation method, a high performance liquid chromatography method, or a supercritical chromatography method. EPA can be produced by collecting the EPA.
- the EPA alkyl ester can be produced by separating and collecting the EPA alkyl ester from the EPA-containing composition.
- the EPA alkyl ester is not particularly limited as long as it is an EPA alkyl ester, and is preferably EPA ethyl ester.
- a mixed fatty acid alkyl ester containing the EPA alkyl ester is prepared from the EPA-containing composition by an alcoholysis method, and then, for example, a urea addition method, cooling separation
- the method can be carried out by separating and collecting the EPA alkyl ester by a method, high performance liquid chromatography or supercritical chromatography.
- Example 1 Production of EPA Using Escherichia coli Producing Mutant OrfB-1 (1) Construction of each expression plasmid [Construction of OrfA protein expression plasmid] According to a method similar to that of Hayashi et al. (Sci. Rep., 2016, 6, 35441), Schizochyrium sp. An expression plasmid pET21-orfA having DNA encoding the OrfA protein (DNA having the nucleotide sequence represented by SEQ ID NO: 4) derived from the (ATCC20888) strain was obtained.
- the obtained DNA and Escherichia coli vector pCOLADuet-1 (manufactured by Merck Millipore) were treated with restriction enzymes NdeI and MfeI, respectively, and the resulting restriction enzyme-treated fragments were ligated to obtain Aurantiochytrium sp.
- An expression plasmid pCOLA-OH4_orfC for OrfC protein derived from OH4 strain was obtained.
- OrfB expression plasmid pCDF-orfB1 (Sci. Rep., 2016, 6, 35441) derived from the strain was treated with AgeI to obtain an AgeI-treated fragment, and the AgeI-treated fragment was obtained using a Blunting high kit (manufactured by Toyobo). The ends of the treated fragments were blunt-ended and then self-ligated.
- pCDF-orfB1 ′ in which the AgeI recognition sequence downstream of the T7 terminator of pCDF-orfB1 was deleted was obtained.
- DNA The DNA fragment obtained by error-prone PCR was purified, treated with restriction enzymes NdeI and AgeI, and ligated with pCDF-OH4_orfBs treated with the same restriction enzymes. From this, a DNA library encoding the mutant OrfB was constructed.
- ⁇ Escherichia coli BLR (DE3) ⁇ fadE was transformed with a DNA library encoding pET21-orfA, pCOLA-OH4_orfC and pSTV-hetI, and pCDF-OH4_orfBs or mutant OrfB.
- the obtained Escherichia coli was inoculated into 2 mL of a Terrific Broth medium (manufactured by Becton, Dickinson and Company) containing 100 mg / L of ampicillin, 20 mg / L of kanamycin, 30 mg / L of chloramphenicol, and 20 mg / L of streptomycin. Shaking culture was performed at 16 ° C. for 16 hours.
- 1 mL of the obtained culture solution was newly prepared in a Terrific Broth medium (Becton Dickinson & Company) containing 100 mg / L ampicillin, 20 mg / L kanamycin, 30 mg / L chloramphenicol, 20 mg / L streptomycin, and 1 mM IPTG. (Manufactured by KK) and inoculated in a 200 mL-winged flask containing 20 mL, and cultured at 230 rpm at 20 ° C for 48 hours.
- a Terrific Broth medium Becton Dickinson & Company
- a culture solution is collected and subjected to the Blight-Dyer method [Bright, e. G. FIG. and @Dyer, W.C. J. (1959) Can. J. Biochem. Physiol. 37, 911-917], the fatty acid was methylated with a boron trifluoride / methanol solution, and analyzed by gas chromatography-mass spectrometry.
- the abundance of DHA and EPA in the culture solution was calculated from the area of the peak corresponding to DHA methyl ester and EPA methyl ester by gas chromatography mass spectrometry, and the abundance ratio of EPA to DHA was also calculated.
- Escherichia coli producing wild-type OrfB did not produce EPA, whereas Escherichia coli transformed with a DNA library encoding mutant OrfB produced a strain that produced EPA.
- the nucleotide sequence of DNA encoding the mutant OrfB expressed by Escherichia coli with improved EPA productivity was determined.
- L-phenylalanine at position 230 in the amino acid sequence of OrfB was replaced with L-leucine
- L-asparagine at position 6 was replaced with L-serine
- L-phenylalanine at position 65 was replaced with L-leucine.
- Table 1 summarizes the results of measuring EPA, DHA, and DPA in the culture solution.
- Example 2 Production of EPA Using Escherichia coli Producing Mutant OrfB-2 (1) Construction of each expression plasmid PCR was performed using pCDF-OH4_orfB obtained in Example 1 (2) as a template and primers represented by SEQ ID NOs: 9 and 17 to encode the N-terminal region of the KS domain of OrfB. A DNA fragment containing the target DNA was amplified.
- PCR was performed using pCDF-OH4_orfB as a template and a primer represented by SEQ ID NO: 16 and a primer represented by SEQ ID NO: 18, 19, 20, 21 or 22, and the amino acid residue at position 230 in the amino acid sequence of OrfB was A DNA fragment containing DNA encoding the C-terminal region of the KS domain of the mutant OrfB in which the group was substituted with L-tryptophan, L-asparagine, glycine, L-aspartic acid or L-alanine was amplified.
- the DNA fragment and pCDF-OH4_orfBs were treated with restriction enzymes NdeI and AgeI, respectively, and the resulting restriction enzyme-treated fragments were ligated to obtain pCDF-OH4_orfB-F230W, pCDF-OH4_orfB-F230N, pCDF-OH4_orfB-F230G, pCDF. -OH4_orfB-F230D and pCDF-OH4_orfB-F230A were obtained.
- the obtained Escherichia coli was inoculated into 2 mL of a Terrific Broth medium (manufactured by Becton, Dickinson and Company) containing 100 mg / L of ampicillin, 20 mg / L of kanamycin, 30 mg / L of chloramphenicol, and 20 mg / L of streptomycin. Shaking culture was performed at 16 ° C. for 16 hours.
- 1 mL of the obtained culture solution was newly prepared in a Terrific Broth medium (Becton Dickinson & Company) containing 100 mg / L ampicillin, 20 mg / L kanamycin, 30 mg / L chloramphenicol, 20 mg / L streptomycin, and 1 mM IPTG. (Manufactured by Ajinomoto Co., Inc.) into a 200 mL-winged flask containing 20 mL, and cultured at 230 rpm at 20 ° C. for 48 hours.
- a Terrific Broth medium Becton Dickinson & Company
- Table 2 shows the results of measuring EPA, DHA and DPA in the culture solution.
- ⁇ PCDF-OH4_orfB-N6S-F230L is manufactured by Aurantiochytrium ⁇ sp. It has a DNA encoding an amino acid sequence in which the sixth amino acid residue is replaced with L-serine and the 230th amino acid residue is replaced with L-leucine in the amino acid sequence of OrfB derived from OH4 strain.
- ⁇ PCDF-OH4_orfB-F65L-F230L is manufactured by Aurantiochytrium ⁇ sp. It has a DNA encoding an amino acid sequence in which the 65th amino acid residue is replaced with L-leucine and the 230th amino acid residue is replaced with L-leucine in the amino acid sequence of OrfB derived from OH4 strain.
- ⁇ PCDF-OF4_orfB-N6S-F65L-F230L is Auranchiochytrium ⁇ sp.
- the obtained Escherichia coli was inoculated into 2 mL of a Terrific Broth medium (manufactured by Becton, Dickinson and Company) containing 100 mg / L of ampicillin, 20 mg / L of kanamycin, 30 mg / L of chloramphenicol, and 20 mg / L of streptomycin. Shaking culture was performed at 16 ° C. for 16 hours.
- 1 mL of the obtained culture solution was newly prepared in a Terrific Broth medium (Becton Dickinson & Company) containing 100 mg / L ampicillin, 20 mg / L kanamycin, 30 mg / L chloramphenicol, 20 mg / L streptomycin, and 1 mM IPTG. (Manufactured by Ajinomoto Co., Inc.) into a 200 mL-winged flask containing 20 mL, and cultured at 230 rpm at 20 ° C. for 48 hours.
- a Terrific Broth medium Becton Dickinson & Company
- Table 3 shows the results of measuring EPA, DHA and DPA in the culture solution.
- Example 4 Production of EPA Using Escherichia coli Producing Mutant OrfB-4 Using the DNA encoding the mutant OrfB consisting of the amino acid sequence obtained by substituting L-leucine for L-phenylalanine at position 230 and L-leucine at position 65 for L-phenylalanine obtained in Example 3, as a template Error-prone PCR was carried out in the same manner as in Example 1 (2), and introduced into Escherichia coli BLR (DE3) ⁇ fadE strain in the same manner as in Example 1 (3) to confirm EPA productivity.
- E3 Escherichia coli BLR
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
1.DHAを生産する能力を有する微生物であって、配列番号2で表されるアミノ酸配列において、6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質(以下、変異型OrfBという。)を含み、且つエイコサペンタエン酸(以下、EPAという。)を生産し得る微生物。
2.DHAを生産する能力を有する微生物であって、配列番号2で表されるアミノ酸配列からなる蛋白質のホモログ蛋白質(以下、OrfBホモログという。)のアミノ酸配列において、OrfBホモログのアミノ酸配列と配列番号2で表されるアミノ酸配列とをアライメントしたときに、配列番号2の6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1に対応するアミノ酸残基が他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質(以下、変異型OrfBホモログという。)を含み、且つEPAを生産し得る微生物。
3.DHAを生産する能力を有する微生物が、ラビリンチュラ類微生物である前記1または2に記載の微生物。
4.ラビリンチュラ類微生物が、オーランチオキトリウム(Aurantiochytrium)属、スラウストキトリウム(Thraustochytrium)属、ウルケニア(Ulkenia)属、パリエチキトリウム(Parietichytrium)属、ラビリンチュラ(Labyrinthula)属、アプラノキトリウム(Aplanochytrium)属、オブロンギキトリウム(Oblongichytrium)属、又はシゾキトリウム(Schizochytrium)属に属するラビリンチュラ類微生物である前記3に記載の微生物。
5.DHAを生産する能力を有する微生物が、DHA代謝経路を有さない微生物にDHAを合成する活性を有する下記(a)~(j)の各ドメインをコードする遺伝子が導入された微生物である前記1または2に記載の微生物。
(a)KSドメイン
(b)MATドメイン
(c)ACPドメイン
(d)KRドメイン
(e)ポリケチドシンターゼデヒドラターゼ(以下、PS-DHという。)ドメイン
(f)CLFドメイン
(g)ATドメイン
(h)FabA様β-ヒドロキシアシル-ACPデヒドラターゼ(以下、FabA-DHという。)ドメイン
(i)ERドメイン
(j)PPTドメイン
6.DHA代謝経路を有さない微生物が、エシェリヒア(Escherichia)属、バチルス(Bacillus)属、コリネバクテリウム(Corynebacterium)属、ヤロウィア(Yarrowia)属、サッカロマイセス(Saccharomyces)属、カンジダ(Candida)属、又はピキア(Pichia)属に属する微生物である前記5に記載の微生物。
7.前記1~6のいずれか1に記載の微生物を培地に培養し、培養物中にEPA又はEPA含有組成物を生成、蓄積させ、該培養物からEPA、又はEPA含有組成物を採取する、EPA又はEPA含有組成物の製造法。
8.下記(I)又は(II)のEPAを生産し得る微生物を用いるEPA又はEPA含有組成物の製造法。
(I)DHAを生産する能力を有する微生物であって、配列番号2で表されるアミノ酸配列において6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる変異型OrfBを含み、且つEPAを生産し得る微生物
(II)DHAを生産する能力を有する微生物であって、OrfBホモログのアミノ酸配列において、OrfBホモログのアミノ酸配列と配列番号2で表されるアミノ酸配列とをアライメントしたときに、配列番号2の6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる変異型OrfBホモログを含み、且つEPAを生産し得る微生物
本発明の微生物は、ドコサヘキサンエン酸(DHA)を生産する能力を有する微生物であって、配列番号2で表されるアミノ酸配列において、6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質(変異型OrfB)を含み、且つエイコサペンタエン酸(EPA)を生産し得ることを特徴とする。
(1)DHA代謝能を有する微生物。
(2)DHA代謝能を有さない微生物を宿主生物として、該宿主生物にDHAを生合成する活性を有するPUFA-PKSを構成するドメインである、KSドメイン、MATドメイン、ACPドメイン、KRドメイン、PS-DHドメイン、CLFドメイン、ATドメイン、FabA-DHドメイン、ERドメイン及びPPTドメインをコードする遺伝子が導入されたことによりDHA生産能を有する微生物。
(a)配列番号2で表されるアミノ酸配列において、6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質
(b)OrfBホモログのアミノ酸配列において、該アミノ酸配列と配列番号2で表されるアミノ酸配列とをアライメントしたときに、配列番号2で表されるアミノ酸配列の6番目、65番目、230番目、231番目及び275番目のアミノ酸残基に対応するアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質。
(i)配列番号2のアミノ酸配列の6番目のアミノ酸残基又はOrfBホモログのアミノ酸配列の該アミノ酸残基に対応するアミノ酸残基がセリンに置換
(ii)配列番号2のアミノ酸配列の65番目のアミノ酸残基又はOrfBホモログのアミノ酸配列の該アミノ酸残基に対応するアミノ酸残基がロイシンに置換
(iii)配列番号2のアミノ酸配列の230番目のアミノ酸残基又はOrfBホモログのアミノ酸配列の該アミノ酸残基に対応するアミノ酸残基がロイシン、L-トリプトファン、L-アスパラギン、グリシン、L-アスパラギン酸又はL-アラニンに置換
(iv)配列番号2のアミノ酸配列の231番目のアミノ酸残基又はOrfBホモログのアミノ酸配列の該アミノ酸残基に対応するアミノ酸残基がスレオニンに置換
(v)配列番号2のアミノ酸配列の275番目のアミノ酸残基又はOrfBホモログのアミノ酸配列の該アミノ酸残基に対応するアミノ酸残基がグリシンに置換
A群:ロイシン、イソロイシン、ノルロイシン、バリン、ノルバリン、アラニン、2-アミノブタン酸、メチオニン、O-メチルセリン、t-ブチルグリシン、t-ブチルアラニン、シクロヘキシルアラニン
B群:アスパラギン酸、グルタミン酸、イソアスパラギン酸、イソグルタミン酸、2-アミノアジピン酸、2-アミノスベリン酸
C群:アスパラギン、グルタミン
D群:リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸
E群:プロリン、3-ヒドロキシプロリン、4-ヒドロキシプロリン
F群:セリン、スレオニン、ホモセリン
G群:フェニルアラニン、チロシン
DHAを生産する能力を有する微生物に変異型OrfB又は変異型OrfBホモログを発現させる方法としては、例えば、以下の(I)及び(II)が挙げられる。
(I)DHAを生産する能力を有する微生物に、変異型OrfB又は変異型OrfBホモログをコードする外来の遺伝子を導入する。
(II)DHAを生産する能力を有する微生物における内因性のOrfB又はOrfBホモログをコードする遺伝子に変異を導入する。
本発明は、上記造成された微生物を培地に培養し、培養物中にEPA又はEPA含有組成物を生成、蓄積させ、該培養物からEPA又はEPA含有組成物を採取することを特徴とする、EPA又はEPA含有組成物の製造法(以下、本発明の製造法という。)を含む。
変異型OrfBを生産する大腸菌を用いたEPAの製造-1
(1)各発現プラスミドの造成
[OrfA蛋白質発現プラスミドの造成]
林ら(Sci.Rep.,2016,6,35441)と同様の方法により、Schizochytrium sp.(ATCC20888)株由来のOrfA蛋白質をコードするDNA(配列番号4で表わされる塩基配列からなるDNA)を有する発現プラスミドpET21-orfAを得た。
常法により抽出したAuranctiochytrium sp.OH4株のゲノムDNAを鋳型に、配列番号7及び8で表わされるプライマーを用いてPCRを行い、OrfC蛋白質をコードするDNA(配列番号3で表わされる塩基配列からなるDNA)を含むDNA断片を得た。得られたDNA及び大腸菌ベクターpCOLADuet-1 (メルクミリポア社製)を制限酵素NdeI及びMfeIでそれぞれ処理し、得られた制限酵素処理断片をライゲーションすることにより、Auranctiochytrium sp.OH4株由来のOrfC蛋白質の発現プラスミドpCOLA-OH4_orfCを得た。
林ら(Sci.Rep.,2016,6,35441)と同様の方法により、Nostoc sp. PCC7120(ATCC27893)株由来のHetI蛋白質をコードするDNA(配列番号5で表わされる塩基配列からなるDNA)を有する発現プラスミドpSTV-hetIを得た。
[野生型OrfB発現プラスミドの造成]
Schizochytrium sp.(ATCC20888)株由来のOrfB発現プラスミドpCDF-orfB1(Sci.Rep.,2016,6,35441)をAgeIで処理してAgeI処理断片を取得し、Blunting highキット(東洋紡社製)を用いて該AgeI処理断片の末端を平滑化したのちセルフライゲーションした。これより、pCDF-orfB1のT7ターミネーター下流のAgeI認識配列が削除されたpCDF-orfB1’を得た。
続いて、pCDF-OH4_orfBsを鋳型とし、配列番号15及び16で表わされるプライマーを用い、TaKaRa Taq Hot Start Version(タカラバイオ社製)を用いてエラープローンPCRを行った。エラープローンPCRにおいては、変異を誘発するため、PCR反応液中のMgClの濃度を5mMとした。
林ら(Sci.Rep.,2016,6,35441)と同様の方法で、アシル-CoAデヒドロゲナーゼFadE(配列番号6で表わされるアミノ酸配列からなる蛋白質)をコードする遺伝子が欠失した大腸菌BLR(DE3)ΔfadE株を造成した。
さらに、230番目のL-フェニルアラニンがL-ロイシンに置換されているアミノ酸配列からなる変異型OrfBをコードするDNAを鋳型として、前記と同様の方法でエラープローンPCRを行い、前記と同様の方法で大腸菌BLR(DE3)ΔfadE株に導入し、EPAの生産性を確認した。
変異型OrfBを生産する大腸菌を用いたEPAの製造-2
(1)各発現プラスミドの造成
実施例1(2)で取得したpCDF-OH4_orfBを鋳型に、配列番号9及び17で表わされるプライマーを用いてPCRを行い、OrfBのKSドメインのN末端領域をコードするDNAを含むDNA断片を増幅した。
pET21-orfA、pCOLA-OH4_orfC及びpSTV-hetI、並びに野生型OrfB又は6種類の変異型OrfBの発現プラスミド(pCDF-OH4_orfBs、pCDF-OH4_orfB-F230L、pCDF-OH4_orfB-F230W、pCDF-OH4_orfB-F230N、pCDF-OH4_orfB-F230G、pCDF-OH4_orfB-F230D又はpCDF-OH4_orfB-F230A)で大腸菌BLR(DE3)ΔfadE株を形質転換した。
変異型OrfBを生産する大腸菌を用いたEPAの製造-3
(1)各発現プラスミドの造成
[pCDF-OH4_orfB-N6S-F230Lの造成]
pCDF-OH4_orfB-F230Lを鋳型に、配列番号23及び16で表わされるプライマーを用いてPCRを行い、OrfBのKSドメインをコードするDNAを含むDNA断片を得た。得られたDNA断片及びpCDF-OH4_orfB-F230Lを制限酵素NdeI及びAgeIでそれぞれ処理し、得られた制限酵素処理断片をライゲーションすることにより、pCDF-OH4_orfB-N6S-F230Lを得た。
pCDF-OH4_orfB-F230Lを鋳型に、配列番号24、25、26及び16で表わされるプライマーを用いてオーバーラップエクステンションPCRを行い、OrfBのKSドメインをコードするDNAを含むDNA断片を得た。得られたDNA断片及びpCDF-OH4_orfB-F230Lを制限酵素NdeI及びAgeIでそれぞれ処理し、得られた制限酵素処理断片をライゲーションすることにより、pCDF-OH4_orfB-F65L-F230Lを得た。
実施例1(4)で取得した、230番目のL-フェニルアラニンがL-ロイシンに、6番目のL-アスパラギンがL-セリンに、65番目のL-フェニルアラニンがL-ロイシンに置換したOrfBを生産する大腸菌よりプラスミドを抽出し、pCDF-OF4_orfB-N6S-F65L-F230Lを得た。
pET21-orfA、pCOLA-OH4_orfC及びpSTV-hetI、並びに野生型OrfB又は4種類の変異型OrfBの発現プラスミド(pCDF-OH4_orfBs、pCDF-OH4_orfB-F230L、pCDF-OH4_orfB-N6S-F230L、pCDF-OH4_orfB-F65L-F230L又はpCDF-OH4_orfB-N6S-F65L-F230L)で大腸菌BLR(DE3)ΔfadE株を形質転換した。
変異型OrfBを生産する大腸菌を用いたEPAの製造-4
実施例3で取得した、230番目のL-フェニルアラニンがL-ロイシンに、65番目のL-フェニルアラニンがL-ロイシンに置換されているアミノ酸配列からなる変異型OrfBをコードするDNAを鋳型として、実施例1(2)と同様の方法でエラープローンPCRを行い、実施例1(3)と同様の方法で大腸菌BLR(DE3)ΔfadE株に導入し、EPAの生産性を確認した。
Claims (8)
- ドコサヘキサエン酸(以下、DHAという。)を生産する能力を有する微生物であって、配列番号2で表されるアミノ酸配列において、6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質(以下、変異型OrfBという。)を含み、且つエイコサペンタエン酸(以下、EPAという。)を生産し得る微生物。
- DHAを生産する能力を有する微生物であって、配列番号2で表されるアミノ酸配列からなる蛋白質のホモログ蛋白質(以下、OrfBホモログという。)のアミノ酸配列において、OrfBホモログのアミノ酸配列と配列番号2で表されるアミノ酸配列とをアライメントしたときに、配列番号2の6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1に対応するアミノ酸残基が他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質(以下、変異型OrfBホモログという。)を含み、且つEPAを生産し得る微生物。
- DHAを生産する能力を有する微生物が、ラビリンチュラ類微生物である請求項1または2に記載の微生物。
- ラビリンチュラ類微生物が、オーランチオキトリウム(Aurantiochytrium)属、スラウストキトリウム(Thraustochytrium)属、ウルケニア(Ulkenia)属、パリエチキトリウム(Parietichytrium)属、ラビリンチュラ(Labyrinthula)属、アプラノキトリウム(Aplanochytrium)属、オブロンギキトリウム(Oblongichytrium)属、又はシゾキトリウム(Schizochytrium)属に属するラビリンチュラ類微生物である請求項3に記載の微生物。
- DHAを生産する能力を有する微生物が、DHA代謝経路を有さない微生物にDHAを合成する活性を有する下記(a)~(j)の各ドメインをコードする遺伝子が導入された微生物である請求項1または2に記載の微生物。
(a)β-ケトアシル-ACPシンターゼ(以下、KSという。)ドメイン
(b)マロニル-CoA:ACPアシルトランスフェラーゼ(以下、MATという。)ドメイン
(c)ACPドメイン
(d)ケトレダクターゼ(以下、KRという。)ドメイン
(e)ポリケチドシンターゼデヒドラターゼ(以下、PS-DHという。)ドメイン
(f)鎖伸長因子(以下、CLFという。)ドメイン
(g)アシルトランスフェラーゼ(以下、ATという。)ドメイン
(h)FabA様β-ヒドロキシアシル-ACPデヒドラターゼ(以下、FabA-DHという。)ドメイン
(i)エノイルACP-レダクターゼ(以下、ERという。)ドメイン
(j)ホスホパンテテイントランスフェラーゼ(以下、PPTという。)ドメイン - DHA代謝経路を有さない微生物が、エシェリヒア(Escherichia)属、バチルス(Bacillus)属、コリネバクテリウム(Corynebacterium)属、ヤロウィア(Yarrowia)属、サッカロマイセス(Saccharomyces)属、カンジダ(Candida)属、又はピキア(Pichia)属に属する微生物である請求項5に記載の微生物。
- 請求項1~6のいずれか1項に記載の微生物を培地に培養し、培養物中にEPA又はEPA含有組成物を生成、蓄積させ、該培養物からEPA、又はEPA含有組成物を採取する、EPA又はEPA含有組成物の製造法。
- 下記(I)又は(II)のEPAを生産し得る微生物を用いるEPA又はEPA含有組成物の製造法。
(I)DHAを生産する能力を有する微生物であって、配列番号2で表されるアミノ酸配列において6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる変異型OrfBを含み、且つEPAを生産し得る微生物
(II)DHAを生産する能力を有する微生物であって、OrfBホモログのアミノ酸配列において、OrfBホモログのアミノ酸配列と配列番号2で表されるアミノ酸配列とをアライメントしたときに、配列番号2の6番目、65番目、230番目、231番目及び275番目のアミノ酸残基の少なくとも1が他のアミノ酸残基に置換されたアミノ酸配列からなる変異型OrfBホモログを含み、且つEPAを生産し得る微生物
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112021002300-3A BR112021002300A2 (pt) | 2018-08-10 | 2019-08-09 | microrganismo que produz ácido eicosapentaenoico e método para a produção de ácido eicosapentaenoico |
US17/266,984 US11613728B2 (en) | 2018-08-10 | 2019-08-09 | Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid |
JP2020535922A JPWO2020032261A1 (ja) | 2018-08-10 | 2019-08-09 | エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法 |
EP19848560.9A EP3835410A4 (en) | 2018-08-10 | 2019-08-09 | EICOSAPENTAIC ACID PRODUCING MICROORGANISM AND PROCESS FOR PRODUCTION OF EICOSAPENTAIC ACID |
CN201980053538.XA CN112601808A (zh) | 2018-08-10 | 2019-08-09 | 生产二十碳五烯酸的微生物和二十碳五烯酸的制造方法 |
US18/169,487 US20230235271A1 (en) | 2018-08-10 | 2023-02-15 | Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid |
JP2023194578A JP2024003202A (ja) | 2018-08-10 | 2023-11-15 | エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-151234 | 2018-08-10 | ||
JP2018151234 | 2018-08-10 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/266,984 A-371-Of-International US11613728B2 (en) | 2018-08-10 | 2019-08-09 | Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid |
US18/169,487 Continuation US20230235271A1 (en) | 2018-08-10 | 2023-02-15 | Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020032261A1 true WO2020032261A1 (ja) | 2020-02-13 |
Family
ID=69414293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/031652 WO2020032261A1 (ja) | 2018-08-10 | 2019-08-09 | エイコサペンタエン酸を生産する微生物及びエイコサペンタエン酸の製造法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US11613728B2 (ja) |
EP (1) | EP3835410A4 (ja) |
JP (2) | JPWO2020032261A1 (ja) |
CN (1) | CN112601808A (ja) |
BR (1) | BR112021002300A2 (ja) |
WO (1) | WO2020032261A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2020032258A1 (ja) * | 2018-08-10 | 2021-08-12 | 協和発酵バイオ株式会社 | 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 |
CN114480148A (zh) * | 2022-01-07 | 2022-05-13 | 南京师范大学 | 一种表达epa合酶基因的裂殖壶菌基因工程菌株、其构建方法及其应用 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
JP2007524377A (ja) * | 2003-03-26 | 2007-08-30 | マーテック・バイオサイエンシーズ・コーポレーション | Pufaポリケチドシンターゼ系およびこれらの使用 |
WO2008144473A2 (en) | 2007-05-16 | 2008-11-27 | Martek Biosciences Corporation | Chimeric pufa polyketide synthase systems and uses thereof |
JP2013055893A (ja) | 2011-09-07 | 2013-03-28 | Nippon Suisan Kaisha Ltd | 高度不飽和脂肪酸濃縮油の製造方法 |
JP2017184690A (ja) * | 2016-04-08 | 2017-10-12 | 協和発酵バイオ株式会社 | 多価不飽和脂肪酸ポリケチドシンターゼ及びその利用 |
JP2018151234A (ja) | 2017-03-13 | 2018-09-27 | 富士通株式会社 | 測距装置,水位計測システム及び測距方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007867A2 (en) * | 1996-08-22 | 1998-02-26 | Bioteknologisk Institut | Metabolically engineered lactic acid bacteria and means for providing same |
US6566583B1 (en) * | 1997-06-04 | 2003-05-20 | Daniel Facciotti | Schizochytrium PKS genes |
US7217856B2 (en) | 1999-01-14 | 2007-05-15 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
US7211418B2 (en) * | 1999-01-14 | 2007-05-01 | Martek Biosciences Corporation | PUFA polyketide synthase systems and uses thereof |
TWI426126B (zh) | 2001-04-16 | 2014-02-11 | Dsm Ip Assets Bv | 多不飽和脂肪酸(pufa)聚乙醯合成酶系統及其用途(二) |
TWI377253B (en) * | 2001-04-16 | 2012-11-21 | Martek Biosciences Corp | Product and process for transformation of thraustochytriales microorganisms |
DE102004017370A1 (de) * | 2004-04-08 | 2005-10-27 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | PUFA-PKS Gene aus Ulkenia |
WO2006135866A2 (en) * | 2005-06-10 | 2006-12-21 | Martek Biosciences Corporation | Pufa polyketide synthase systems and uses thereof |
CN102741267B (zh) | 2009-03-19 | 2020-06-23 | 帝斯曼知识产权资产有限公司 | 多不饱和脂肪酸合酶核酸分子和多肽,及其组合物、制备方法和用途 |
TW201144442A (en) * | 2010-05-17 | 2011-12-16 | Dow Agrosciences Llc | Production of DHA and other LC-PUFAs in plants |
JP6298770B2 (ja) * | 2013-01-18 | 2018-03-20 | 協和発酵バイオ株式会社 | ドコサヘキサエン酸を生産する微生物及びその利用 |
-
2019
- 2019-08-09 CN CN201980053538.XA patent/CN112601808A/zh active Pending
- 2019-08-09 BR BR112021002300-3A patent/BR112021002300A2/pt unknown
- 2019-08-09 WO PCT/JP2019/031652 patent/WO2020032261A1/ja unknown
- 2019-08-09 JP JP2020535922A patent/JPWO2020032261A1/ja active Pending
- 2019-08-09 EP EP19848560.9A patent/EP3835410A4/en active Pending
- 2019-08-09 US US17/266,984 patent/US11613728B2/en active Active
-
2023
- 2023-02-15 US US18/169,487 patent/US20230235271A1/en active Pending
- 2023-11-15 JP JP2023194578A patent/JP2024003202A/ja active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
JP2007524377A (ja) * | 2003-03-26 | 2007-08-30 | マーテック・バイオサイエンシーズ・コーポレーション | Pufaポリケチドシンターゼ系およびこれらの使用 |
WO2008144473A2 (en) | 2007-05-16 | 2008-11-27 | Martek Biosciences Corporation | Chimeric pufa polyketide synthase systems and uses thereof |
JP2013055893A (ja) | 2011-09-07 | 2013-03-28 | Nippon Suisan Kaisha Ltd | 高度不飽和脂肪酸濃縮油の製造方法 |
JP2017184690A (ja) * | 2016-04-08 | 2017-10-12 | 協和発酵バイオ株式会社 | 多価不飽和脂肪酸ポリケチドシンターゼ及びその利用 |
JP2018151234A (ja) | 2017-03-13 | 2018-09-27 | 富士通株式会社 | 測距装置,水位計測システム及び測距方法 |
Non-Patent Citations (34)
Title |
---|
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS |
"Gene Expression Technology: Methods in Enzymology", vol. 185, 1990, ACADEMIC PRESS |
"Molecular Cloning, A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
AGRIC. BIOL. CHEM., vol. 53, 1989, pages 277 |
ANN. REV. BIOCHEM., vol. 52, 1983, pages 537 - 579 |
ANNU. NUTR. METABOL., vol. 35, 1991, pages 128 - 131 |
APPL. ENVIRON. MICROBIOL., vol. 75, 2009, pages 5529 - 5535 |
APPL. MICROBIOL. BIOTECHNOL., 2018, pages 847 - 856 |
APPL. MICROBIOL. BIOTECHNOL., vol. 53, 2000, pages 674 - 679 |
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 20, 2007, pages 6378 - 6385 |
BIOSCI. BIOTECHNOL. BIOCHEM., vol. 71, 2007, pages 2905 |
BLIGH, E. G.DYER, W. J., CAN. J. BIOCHEM. PHYSIOL., vol. 37, 1959, pages 911 - 917 |
FEMS MICROBIOL. LETT., vol. 295, 2009, pages 170 - 176 |
GENE, vol. 33, 1985, pages 103 |
HAYASHI ET AL., SCI. REP., vol. 6, 2016, pages 35441 |
J. MOL. BIOL., vol. 215, 1990, pages 403 |
J.AM. CLIN. NUTR., vol. 13, 1994, pages 658 - 664 |
KARLIN, ALTSCHUL, METHODS ENZYMOL., vol. 183, 1990, pages 63 |
KARLIN, ALTSCHUL, PRO. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
KORETARO TAKAHASHI, JOURNAL OF JAPAN OIL CHEMIST'S SOCIETY, vol. 40, 1991, pages 931 - 941 |
MOL. MICROBIOL., vol. 55, 2005, pages 137 |
NUCLEIC ACIDS RES., vol. 16, 1988, pages 6127 |
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487 |
NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 4431 |
PLANT PHYSIOL. BIOCHEM., vol. 47, 2009, pages 472 - 478 |
PLOS ONE, vol. 6, 2011, pages e20146 |
PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2110 |
PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 |
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 4306 |
PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 6641 - 6645 |
SCIENCE, vol. 293, 2001, pages 290 - 293 |
See also references of EP3835410A4 |
SHOHEI HAYASHI ET AL.: "Enhanced production of polyunsaturated fatty acids by enzyme engineering of tandem acyl carrier proteins", SCIENTIFIC REPORTS, vol. 6, 18 October 2016 (2016-10-18), pages 1 - 10, XP055373222 * |
YOSHITAKE ORIKASA ET AL: "Recombinant production of docosahexaenoic acid in a polyketide biosynthesis mode in Escherichia coli", BIOTHECHNOLOGY LETTERS, vol. 28, no. 22, 19 September 2006 (2006-09-19), pages 1841 - 1847, XP019433307 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024003202A (ja) | 2024-01-11 |
EP3835410A4 (en) | 2022-05-18 |
CN112601808A (zh) | 2021-04-02 |
US20210309960A1 (en) | 2021-10-07 |
BR112021002300A2 (pt) | 2021-05-04 |
US20230235271A1 (en) | 2023-07-27 |
EP3835410A1 (en) | 2021-06-16 |
JPWO2020032261A1 (ja) | 2021-08-10 |
US11613728B2 (en) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230235271A1 (en) | Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid | |
Vogt et al. | Pushing product formation to its limit: metabolic engineering of Corynebacterium glutamicum for L-leucine overproduction | |
US7211418B2 (en) | PUFA polyketide synthase systems and uses thereof | |
JP6518317B2 (ja) | フィードバック抵抗性アセトヒドロキシ酸シンターゼ変異体及びそれを用いたl−バリンの生産方法 | |
RU2675506C2 (ru) | Способ получения l-лейцина, l-валина, l-изолейцина, альфа-кетоизовалерата, альфа-кето-бета-метилвалерата или альфа-кетоизокапроата с использованием рекомбинантных коринебактерий, содержащих оперон ilvbn, который можно индуцировать пропионатом | |
AU2008249169B2 (en) | PUFA polyketide synthase systems and uses thereof | |
JP6816970B2 (ja) | 多価不飽和脂肪酸ポリケチドシンターゼ及びその利用 | |
US10968437B2 (en) | Factors for the production and accumulation of polyunsaturated fatty acids (PUFAs) derived from PUFA synthases | |
US9574215B2 (en) | Production of fatty acids by heterologous expression of gene clusters from myxobacteria | |
WO2020032258A1 (ja) | 多価不飽和脂肪酸を生産する微生物及び多価不飽和脂肪酸の製造法 | |
JP6619229B2 (ja) | アラキドン酸生産ポリケチドシンターゼ及びその利用 | |
Lee et al. | Isolation and characterization of the eicosapentaenoic acid biosynthesis gene cluster from Shewanella sp. BR-2 | |
KR20240043794A (ko) | Cdp-콜린의 제조에 이용하는 재조합 미생물 및 상기 재조합 미생물을 이용하는 cdp-콜린의 제조 방법 | |
KR101617883B1 (ko) | 젖산 내성 강화능 및 고생산능을 갖는 루코노스톡 메센테로이데스 lma92a 균주 및 이를 이용한 젖산 생산 방법 | |
AU2012203480A1 (en) | PUFA polyketide synthase systems and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19848560 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020535922 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021002300 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019848560 Country of ref document: EP Effective date: 20210310 |
|
ENP | Entry into the national phase |
Ref document number: 112021002300 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210208 |